2019-06-20

FDA grants Camurus IND application to enter Phase 3 study with CAM2029 for treatment of acromegaly

The FDA has approved Camurus’ Investigational New Drug application to initiate a Phase 3 study with CAM2029 once-monthly octreotide subcutaneous depot for treatment of acromegaly.

The study will be performed at around 50 clinical sites in the US and in Europe and is expected to be completed early 2021.

Read more at Camurus’ website: https://www.camurus.com/pressreleases/

Acquisition of Scan Coin property

On April 18, 2017 the purchase deed was signed and Sandberg Development is now the owner of the property.

2017-05-18

Refurbishment of production facilities complete

One year after the reconstruction work started, the new production facilities were completed in March 2017.

2016-04-28

Refurbishment of production and office facilities

In March 2016 reconstruction and extension work started at our premises on Jägershillgatan 15 in Malmö. The first pa…

2016-01-14

Sandberg Development sponsor of Star for Life

From 2015 Sandberg Development is a sponsor of Star for Life, an educational/motivational programme, the aim of whic…

2016-01-07

Camurus's initial public offering a success

On Thursday December 3, 2015, Camurus started its first day of trading on Nasdaq Stockholm. The share price increase…